Transplant Failure Clinical Trial
Official title:
Activated Cytotoxic T-lymphocytes CD8+/HLA-DR+ and Acute Cellular Rejection After Lung Transplantation
The objectives of the study is to identify associations between acute rejection and the increase of T (CD4/CD8) and B circulating lymphocytes expressing specific markers of activation and differentiation (HLA-DR, CD25, CD38, CD45RO, CCR7). 110 adults over 18 years, on national waiting list for a first lung transplantation in the centers of Marseille and Strasbourg, whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will be included. Peripheral venous blood sampling just prior to pulmonary transplantation, at day 15 and one month post-transplant will be realized for lymphocyte phenotyping by flow cytometry (CD45, CD3, CD4, CD8, CD19, HLA-DR, CD25, CD38, CD45RO, CCR7). Acute rejection will be evaluated at 1 month and 1 year post-transplant by trans-bronchial biopsies. The two main perspectives are to 1) find a specific, non-invasive, blood-based diagnostic marker of acute post-lung transplant rejection with diagnostic performance equivalent to trans-bronchial biopsy 2) demonstrate a specific blood marker, non-invasive, predictive of acute rejection in order to adapt immunosuppressive therapy early and reduce the occurrence of this risk.
The objectives of the study is to identify associations between acute rejection and the increase of T (CD4/CD8) and B circulating lymphocytes expressing specific markers of activation and differentiation (HLA-DR, CD25, CD38, CD45RO, CCR7). 110 adults over 18 years, on national waiting list for a first lung transplantation in the centers of Marseille and Strasbourg (France), whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will be included. Peripheral venous blood sampling just prior to pulmonary transplantation, at day 15 and one month post-transplant will be realized for lymphocyte phenotyping by flow cytometry (CD45, CD3, CD4, CD8, CD19, HLA-DR, CD25, CD38, CD45RO, CCR7). Acute rejection will be evaluated at 1 month and 1 year post-transplant by trans-bronchial biopsies. The two main perspectives are to 1) find a specific, non-invasive, blood-based diagnostic marker of acute post-lung transplant rejection with diagnostic performance equivalent to trans-bronchial biopsy 2) demonstrate a specific blood marker, non-invasive, predictive of acute rejection in order to adapt immunosuppressive therapy early and reduce the occurrence of this risk. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06080490 -
Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
|
||
| Recruiting |
NCT06116721 -
Evaluation of APOL1 Gene Variants in Kidney Donors and Their Impact on Long-term Renal Function in Donors and Recipients
|
||
| Enrolling by invitation |
NCT04217343 -
NCAMR-CAMR Allosure Study
|
||
| Completed |
NCT04783818 -
Adjuvant Radiotherapy's Effect on One and Two Stages Prosthetic Breast Reconstruction and on Autologous Reconstruction
|
||
| Completed |
NCT04854525 -
Breast Reconstruction in Previously Irradiated Breast
|
||
| Recruiting |
NCT06346665 -
The Transplant Cohort of the German Center for Infection Research
|
||
| Completed |
NCT03723317 -
Associated Balance of Risk Score - Comprehensive Complication Index for the Prediction of Post-transplant Survival
|
||
| Active, not recruiting |
NCT03882164 -
Blood-Bile Ratio Tacrolimus After Liver Transplantation
|
||
| Recruiting |
NCT04360031 -
The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation
|
||
| Active, not recruiting |
NCT03575910 -
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
|
||
| Active, not recruiting |
NCT05184426 -
MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)
|